These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?
    Author: Catalanotti F, Solit DB.
    Journal: Clin Cancer Res; 2012 May 01; 18(9):2420-2. PubMed ID: 22442059.
    Abstract:
    The RAF inhibitor vemurafenib has unprecedented activity in BRAF-mutant melanomas, but resistance invariably develops. As Hsp90 is required for the stability of several of the oncoproteins that mediate RAF inhibitor resistance, inhibitors of this cellular chaperone may be effective in patients with intrinsic or acquired resistance to RAF inhibitors.
    [Abstract] [Full Text] [Related] [New Search]